The FDA schedules a joint advisory committee meeting in November 2022 to review Perrigo's (PRGO) regulatory filing for the first-ever over-the-counter birth control pill.
The FDA has set a date to review what could become the first over-the-counter birth control pill approved in the U.S. The regulatory agency scheduled a joint meeting of its Nonprescription Drugs Advisory Committee and the Obstetrics, Reproductive and Urologic Drugs Advisory Committee to review the application on November 18. In July, the company submitted its application to the FDA for the first-ever over-the-counter (OTC) birth control pill, the first such request for this type of contraception
Perrigo Co Plc said on Monday that the U.S. Food and Drug Administration has scheduled a meeting of external experts on Nov. 18 to review the application of its daily birth control pill for over-the-counter (OTC) use. Contraception access has taken the spotlight since the U.S. Supreme Court's decision in June to overturn the 1973 Roe v. Wade case that legalized abortion nationwide. The FDA meeting for Perrigo's prescription drug, Opill, is set to happen about four months after unit HRA Pharma's application to the health agency.